Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
#1370 68Ga-DOTATOC PET and Gene Expression Profile in Patients with Neuroendocrine Carcinomas
Introduction: Somatostatin receptor expression on both protein and gene expression levels were compared with in vivo 68Ga-DOTATOC PET/CT in patients with neuroendocrine carcinomas (NEC).
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author: Olsen I
Authors: Olsen I, Langer S, Federspiel B, Oxbøl J, Loft A,
Keywords: neuroendocrine carcinoma, gene expression, 68Ga-DOTATOC, IHC, SSTR2,
Introduction: Data on G3-NET and NEC are limited. No standard therapy following platinum-etoposide failure is established and first-line therapy in G3-NET is not codified.
Conference: 11th Annual ENETSConcerence (2014)
Presenting Author:
Authors: Heetfeld M, Rinke A, Borbath I, Crespo G, Olsen I,
Keywords: gastrointestinal cancer, neuroendocrine carcinoma, grade 3 NET, Ki-67, chemotherapy,
Introduction: Aggressive neuroendocrine neoplasms (NEN) encompass both poorly differentiated carcinomas (NEC) and high grade neuroendocrine tumors (G3-NET) with a Ki-67 index >20%; WHO 2010.
Conference: 11th Annual ENETSConcerence (2014)
Presenting Author: olsen i
Authors: Olsen I, Borbath I, Heetfeld M, Walter T, Barriuso J,
Keywords: neuroendocrine carcinoma, Ki-67, immunohistochemistry, treatment,
#776 Goblet Cell Carcinoids: Characteristics of a Danish Cohort of 85 Patients
Introduction: Appendiceal Goblet cell carcinoids (GCC) exhibit neuroendocrine and adenocarcinoma features.
Conference: 10th Annual ENETSConcerence (2013)
Presenting Author:
Authors: Olsen I, Holt N, Langer S, Federspiel B, Hasselby J,
Keywords: prognosis,
Introduction: Knowledge of the clinical efficacy of treatment beyond first line of poorly differentiated neuroendocrine carcinomas (PDEC) is sparse. Temozolomide (TMZ) has shown effect in well-differentiated NET.
Conference: 8th Annual ENETSConcerence (2011)
Presenting Author:
Authors: Olsen I, Federspeil B, Kjaer A, Palnæs Hansen C, Knigge U,
Keywords: PDEC, poorly differentiated carcinomas, temozolomide, second line treatment,